$PMCB
PharmaCyte Biotech, Inc. Stock $pmcb

$pmcb Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-K Financial Statement

#000168316823005175 Filed on July 31, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2023
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.970M	$817.4K	$5.987M
YoY Change	29.49%	-34.8%	61.76%
% of Gross Profit
Research & Development	$104.5K	$85.87K	$468.5K
YoY Change	-34.4%	-66.2%	-32.19%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.075M	$903.3K	$6.455M
YoY Change	23.49%	-40.09%	46.98%
Operating Profit	-$2.075M		-$6.455M
YoY Change	23.49%		46.98%
Interest Expense	$880.0K	$722.9K	$1.938M
YoY Change		735.09%	380548.33%
% of Operating Profit
Other Income/Expense, Net	-$1.108M	$54.01K	$202.0K
YoY Change	-917.11%	-3540.13%	32.15%
Pretax Income	-$3.180M	-$126.3K	-$4.316M
YoY Change	105.82%	-91.12%	1.81%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$3.183M	-$126.3K	-$4.316M
YoY Change	106.04%	-91.12%	1.81%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.28		-$0.22
Diluted Earnings Per Share	-$0.28	-$0.01	-$0.22
COMMON SHARES
Basic Shares Outstanding	8.778M shares		19.49M shares
Diluted Shares Outstanding	12.60M shares		19.49M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$74.66M	$68.04M	$68.04M
YoY Change	-9.2%	-20.33%	-20.33%
Cash & Equivalents	$74.66M	$68.04M
Short-Term Investments
Other Short-Term Assets	$90.00K	$107.7K	$107.7K
YoY Change	219.72%	14.35%	14.35%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$74.75M	$68.15M	$68.15M
YoY Change	-9.12%	-20.29%	-20.29%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles	$3.549M	$3.549M
YoY Change		0.0%
Long-Term Investments	$1.572M	$1.572M	$1.572M
YoY Change	0.0%	0.0%	0.0%
Other Assets	$10.00K	$7.690K	$7.690K
YoY Change	30.04%	0.0%	0.0%
Total Long-Term Assets	$5.129M	$5.129M	$5.129M
YoY Change	0.0%	0.0%	0.0%
TOTAL ASSETS
Total Short-Term Assets	$74.75M	$68.15M	$68.15M
Total Long-Term Assets	$5.129M	$5.129M	$5.129M
Total Assets	$79.88M	$73.28M	$73.28M
YoY Change	-8.59%	-19.14%	-19.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$718.1K	$128.3K	$128.3K
YoY Change	28.46%	-37.53%	-37.53%
Accrued Expenses	$480.0K	$458.3K	$458.3K
YoY Change	-9.48%	-8.16%	-8.16%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.518M	$586.6K	$586.6K
YoY Change	39.35%	-16.72%	-16.72%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$18.88M
YoY Change
Total Long-Term Liabilities	$18.88M	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.518M	$586.6K	$586.6K
Total Long-Term Liabilities	$18.88M	$0.00	$0.00
Total Liabilities	$20.40M	$586.6K	$586.6K
YoY Change	1772.39%	-16.72%	-16.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$119.5M	-$116.0M
YoY Change	5.54%	3.86%
Common Stock	$2.167K	$2.160K
YoY Change	0.32%	4.25%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$40.28M
YoY Change	1826.61%
Treasury Stock Shares
Shareholders Equity	$42.73M	$72.69M	$72.69M
YoY Change
Total Liabilities & Shareholders Equity	$79.88M	$73.28M	$73.28M
YoY Change	-8.59%	-19.14%	-19.14%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2023
OPERATING ACTIVITIES
Net Income	-$3.183M	-$126.3K	-$4.316M
YoY Change	106.04%	-91.12%	1.81%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	$343.0K	-$288.4K	-$3.794M
YoY Change	-131.63%	-75.8%	-7.86%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$4.307M	-$13.56M
YoY Change			-115.52%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$6.279M	-4.307M	-13.56M
YoY Change	-400.44%	8375.91%	-115.53%
NET CHANGE
Cash From Operating Activities	$343.0K	-288.4K	-3.794M
Cash From Investing Activities	$0.00	0.000	0.000
Cash From Financing Activities	$6.279M	-4.307M	-13.56M
Net Change In Cash	$6.623M	-4.595M	-17.35M
YoY Change	-308.71%	269.77%	-120.86%
FREE CASH FLOW
Cash From Operating Activities	$343.0K	-$288.4K	-$3.794M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001157075
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	PMCB	Stock Issued Fractional Shares Reverse Stock Split StockIssuedFractionalSharesReverseStockSplit		usd
CY2023	PMCB	Stock Issued Fractional Shares Reverse Stock Split StockIssuedFractionalSharesReverseStockSplit		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-04-30
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40699
CY2023	dei	Entity Registrant Name EntityRegistrantName	PHARMACYTE BIOTECH, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	62-1772151
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3960 Howard Hughes Parkway
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 500
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Las Vegas
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NV
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	89169
CY2023	dei	City Area Code CityAreaCode	(917)
CY2023	dei	Local Phone Number LocalPhoneNumber	595-2850
CY2023	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.0001 Per Share
CY2023	dei	Trading Symbol TradingSymbol	PMCB
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Public Float EntityPublicFloat	54212148	usd
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8778101	shares
CY2023	dei	Auditor Firm AuditorFirmId	32
CY2023	dei	Auditor Name AuditorName	Armanino
CY2023	dei	Auditor Location AuditorLocation	Irvine, California
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	68039936	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	85400656	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	107681	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	94172	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	68147617	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	85494828	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3549427	usd
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3549427	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	1572193	usd
CY2022Q2	us-gaap	Equity Method Investments EquityMethodInvestments	1572193	usd
CY2023Q2	us-gaap	Other Assets OtherAssets	7688	usd
CY2022Q2	us-gaap	Other Assets OtherAssets	7688	usd
CY2023Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	5129308	usd
CY2022Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	5129308	usd
CY2023Q2	us-gaap	Assets Assets	73276925	usd
CY2022Q2	us-gaap	Assets Assets	90624136	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	128281	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	205361	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	458300	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	499009	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	586581	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	704370	usd
CY2023Q2	us-gaap	Liabilities Liabilities	586581	usd
CY2022Q2	us-gaap	Liabilities Liabilities	704370	usd
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	133333334	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	133333334	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21602078	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16793980	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20721047	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20721047	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	2160	usd
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	2072	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	202230583	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	201582107	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-115958773	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111648656	usd
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4808098	shares
CY2022Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2023Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	13560623	usd
CY2022Q2	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	-0	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-23003	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-15757	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	72690344	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	89919766	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	73276925	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	90624136	usd
CY2023	us-gaap	Revenues Revenues	0	usd
CY2022	us-gaap	Revenues Revenues	0	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	468536	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	690937	usd
CY2023	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1234956	usd
CY2022	us-gaap	Labor And Related Expense LaborAndRelatedExpense	1544751	usd
CY2023	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	951347	usd
CY2022	us-gaap	Noninterest Expense Directors Fees NoninterestExpenseDirectorsFees	256490	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	2687978	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	809489	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1112677	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1090347	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	6455494	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4392014	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-6455494	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-4392014	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	1937499	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	157645	usd
CY2023	us-gaap	Interest Expense InterestExpense	-0	usd
CY2022	us-gaap	Interest Expense InterestExpense	509	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	202002	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4283	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2139501	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	152853	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4315993	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4239161	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19489204	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15521654	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19489204	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15521654	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4315993	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4239161	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-7246	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	4625	usd
CY2023	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-7246	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	4625	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4323239	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4234536	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	6679451	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	33146	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	34846	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	82613000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	44810	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	4749049	usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	4625	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4239161	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	89919766	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	7334	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2278	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	880	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	638072	usd
CY2023	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	5876	usd
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Before Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent	-7246	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4315993	usd
CY2023	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	13560623	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	72690344	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4315993	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4239161	usd
CY2023	us-gaap	Other Noncash Expense OtherNoncashExpense	171744	usd
CY2022	us-gaap	Other Noncash Expense OtherNoncashExpense	0	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	2278	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	34846	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	7334	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	33146	usd
CY2023	PMCB	Share Based Compensation Options ShareBasedCompensationOptions	638072	usd
CY2022	PMCB	Share Based Compensation Options ShareBasedCompensationOptions	44810	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13509	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	21041	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-0	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	316	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-242948	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	33100	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-40709	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2703	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3793731	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4117319	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2023	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	-0	usd
CY2022	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	50805	usd
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	13560623	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	-0	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	880	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	87362049	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13559743	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	87311244	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-7246	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4625	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17360720	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	83198550	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85400656	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2202106	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	68039936	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85400656	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1600	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	509	usd
CY2023	PMCB	Noncash Equity Issuance Costs NoncashEquityIssuanceCosts	0	usd
CY2022	PMCB	Noncash Equity Issuance Costs NoncashEquityIssuanceCosts	34477000	usd
CY2021Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1:1500
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	281269	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y29D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.94
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	281269	shares
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zDpCt5taN5ad" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_864_zFBgOP4e6Ptj">Use of Estimates in the Preparation of Financial Statements</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of the Company’s consolidated financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Company’s consolidated financial position and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	3549427	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	468536	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	690937	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_znBFg2q9ul32" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_86D_zAIsPGIBBRT1">Concentration of Credit Risk</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has no significant off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains most of its cash balance at financial institutions located in throughout the United States. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation up to $250,000. Uninsured balances aggregated approximately $<span id="xdx_901_eus-gaap--CashUninsuredAmount_c20230430_pp0p0" title="Uninsured cash balances">279,000</span> and $<span id="xdx_90D_eus-gaap--CashUninsuredAmount_iI_pp0p0_c20220430_zb8V0f0TxDZ2" title="Uninsured cash balances">35,000,000</span> at April 30, 2023 and 2022, respectively. The Company has not experienced any losses in such accounts. Management believes it is not exposed to any significant credit risk on cash.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
CY2023Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	279000	usd
CY2022Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	35000000	usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	112894	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	118062	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	287310	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	377155	usd
CY2023Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	58096	usd
CY2022Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	3793	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	458300	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	499009	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.94
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	23420	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	19341	usd
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15732671	usd
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	15138850	usd
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	369666	usd
CY2022Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	584321	usd
CY2023Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	93316	usd
CY2022Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	0	usd
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	33688	usd
CY2022Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	35230	usd
CY2023Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16229341	usd
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	15758401	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16229341	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15758401	usd
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	470940	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-739798	usd
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-906359	usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations	-890224	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-369017	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-362448	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	-12462	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	20508	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	470940	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-739798	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	405057	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1976324	usd
CY2023	PMCB	Net Valuation Allowance For State Tax Deductions NetValuationAllowanceForStateTaxDeductions	420300	usd
CY2022	PMCB	Net Valuation Allowance For State Tax Deductions NetValuationAllowanceForStateTaxDeductions	0	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-8459	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-4362	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q2	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4315993	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-4239161	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19489204	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15521654	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19489204	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15521654	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10172116	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10813635	shares
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	10000000	usd
CY2023Q2	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	4808098	shares
CY2023Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	6497473	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15758401	usd
CY2023	PMCB	Deferred Tax Assets Valuation Allowance Charges DeferredTaxAssetsValuationAllowanceCharges	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	470940	usd
CY2023	PMCB	Deferred Tax Assets Valuation Allowance Deductions DeferredTaxAssetsValuationAllowanceDeductions	0	usd
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16229341	usd
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16498199	usd
CY2022	PMCB	Deferred Tax Assets Valuation Allowance Charges DeferredTaxAssetsValuationAllowanceCharges	0	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-739798	usd
CY2022	PMCB	Deferred Tax Assets Valuation Allowance Deductions DeferredTaxAssetsValuationAllowanceDeductions	0	usd
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15758401	usd

Files In Submission

Name	View Source	Status
0001683168-23-005175-index-headers.html	Edgar Link	pending
0001683168-23-005175-index.html	Edgar Link	pending
0001683168-23-005175.txt	Edgar Link	pending
0001683168-23-005175-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pharmacyte_ex2101.htm	Edgar Link	pending
pharmacyte_ex2301.htm	Edgar Link	pending
pharmacyte_ex3101.htm	Edgar Link	pending
pharmacyte_ex3102.htm	Edgar Link	pending
pharmacyte_ex3201.htm	Edgar Link	pending
pharmacyte_ex3202.htm	Edgar Link	pending
pharmacyte_i10k-043023.htm	Edgar Link	pending
pmcb-20230430.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
pmcb-20230430_cal.xml	Edgar Link	unprocessable
pmcb-20230430_lab.xml	Edgar Link	unprocessable
pmcb-20230430_def.xml	Edgar Link	unprocessable
pmcb-20230430_pre.xml	Edgar Link	unprocessable
pharmacyte_i10k-043023_htm.xml	Edgar Link	completed
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PMCB
PharmaCyte Biotech, Inc. Stock $pmcb

2023 Q3 Form 10-K Financial Statement

#000168316823005175 Filed on July 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PMCB PharmaCyte Biotech, Inc. Stock $pmcb

2023 Q3 Form 10-K Financial Statement

#000168316823005175 Filed on July 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PMCB
PharmaCyte Biotech, Inc. Stock $pmcb